Search
Akebia Therapeutics Inc
AKBAAdd to Watchlist
1.240USD
+0.030+2.48%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
332.19MMarket Cap
LossP/E TTM
More Details of Akebia Therapeutics Inc Company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Akebia Therapeutics Inc Info
Ticker SymbolAKBA
Company nameAkebia Therapeutics Inc
IPO dateMar 20, 2014
CEOButler (John P)
Number of employees181
Security typeOrdinary Share
Fiscal year-endMar 20
Address245 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16178712098
Websitehttps://akebia.com/
Ticker SymbolAKBA
IPO dateMar 20, 2014
CEOButler (John P)
Company Executives of Akebia Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+29.06%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
49.35K
-113.52%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
FAQs
Who are the top five shareholders of Akebia Therapeutics Inc?
The top five shareholders of Akebia Therapeutics Inc are: Mr. John P. Butler
How many institutions hold shares of Akebia Therapeutics Inc (AKBA)?
As of 2026Q1, 351 institutions hold shares of Akebia Therapeutics Inc, with a combined market value of approximately 125.97M, accounting for 46.96% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -14935721.00.